Taken together, these data demonstrate the utility of our Reck-promoter-reporter assay using YM3 cells for discovering promising candidates for cancer therapeutics, which include anti-metastatic drugs with low toxicity as well as conventional classes of anticancer drugs. Here, RECK is linked to cancer.